Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity
Authors:
- 30 December 2008
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 52 (2) , 379-388
Abstract
Here, we describe the identification of a clinical candidate via structure-based optimization of a ligand efficient pyrazole-benzimidazole fragment. Aurora kinases play a key role in the regulation of mitosis and in recent years have become attractive targets for the treatment of cancer. X-ray crystallographic structures were generated using a novel soakable form of Aurora A and were used to drive the optimization toward potent (IC50 ≈ 3 nM) dual Aurora A/Aurora B inhibitors. These compounds inhibited growth and survival of HCT116 cells and produced the polyploid cellular phenotype typically associated with Aurora B kinase inhibition. Optimization of cellular activity and physicochemical properties ultimately led to the identification of compound 16 (AT9283). In addition to Aurora A and Aurora B, compound 16 was also found to inhibit a number of other kinases including JAK2 and Abl (T315I). This compound demonstrated in vivo efficacy in mouse xenograft models and is currently under evaluation in phase I clinical trials.Keywords
This publication has 38 references indexed in Scilit:
- Discovery of a potent and selective Aurora kinase inhibitorBioorganic & Medicinal Chemistry Letters, 2008
- A Pentacyclic Aurora Kinase Inhibitor (AKI-001) with High in Vivo Potency and Oral BioavailabilityJournal of Medicinal Chemistry, 2008
- Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistryBioorganic & Medicinal Chemistry Letters, 2008
- Recent Developments in Fragment-Based Drug DiscoveryJournal of Medicinal Chemistry, 2008
- The influence of drug-like concepts on decision-making in medicinal chemistryNature Reviews Drug Discovery, 2007
- Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinaseProceedings of the National Academy of Sciences, 2007
- Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approachMolecular Cancer Therapeutics, 2006
- Ligand efficiency: a useful metric for lead selectionDrug Discovery Today, 2004
- The cellular geography of Aurora kinasesNature Reviews Molecular Cell Biology, 2003
- A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancersThe EMBO Journal, 1998